Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aura Biosciences, Inc. (AURA : NSDQ)

• Company Description    Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company's lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass. Number of Employees: 52

• Price / Volume Information    Yesterday's Closing Price: $16.32 Daily Weekly Monthly 20 Day Moving Average: 48,040 shares Shares Outstanding: 29.26 (millions) Market Capitalization: $477.52 (millions) Beta: 52 Week High: $26.16 52 Week Low: $13.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.80% 2.13% 12 Week -8.83% -1.07% Year To Date -3.89% 14.29%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 85 BOLTON STREET - CAMBRIDGE,MA 02140 USA ph: 617-500-8864 fax: - aura@argotpartners.com http://www.aurabiosciences.com

• General Corporate Information    Officers Elisabet de los Pinos - President and Chief Executive Officer David Johnson - Chairman of the Board of Directors Julie Feder - Chief Financial Officer Giovanni Mariggi - Director Anthony Mattessich - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 05153U107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 29.26 Most Recent Split Date: (:1) Beta: Market Capitalization: $477.52 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.03 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.38 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - 27.90 12/31/21 - 21.14 09/30/21 - 14.31 Quick Ratio 03/31/22 - 27.90 12/31/21 - 21.14 09/30/21 - 14.31 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 4.82 12/31/21 - 5.21 09/30/21 - -4.61 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - - Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - -

Powered by Zacks Investment Research ©